An observational study in Hypoxemia, sponsored by Min Su. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Min Su · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies in Hypoxia with a site in China — 44 open to participants now, 45 under way, none of them phase 3. Hypoxia · China.
Among the 97 studies in Hypoxia with a site in China, this one is the 5th largest by planned enrollment of the 19 observational ones that give a count, is one of 19 that started in 2026, is one of 19 observational ones, reaches primary completion later than 41 of the 44 other live ones, and was the 97th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →44 of the 97 studies in Hypoxia with a site in China are open now. Recruiting first, the newest first:
Nanjing First Hospital, Nanjing Medical University · Sites in China
Ages 18+
General Hospital of Ningxia Medical University · Sites in China
Ages 18+
General Hospital of Ningxia Medical University · Sites in China
Ages 18+
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18+
Wenxian Li · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 1 · Phase 4 3
First in 2009; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 772 is above the median of 79 across 279 observational studies indexed under Hypoxia.
Median enrollment 240 across the 78 interventional studies, 120 across the 19 observational. Of the 30 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 97 have an industry lead sponsor. The 10 most frequent:
Min Su is the lead sponsor of 13 studies on the registry; 10 are open to participants now.
Min Su has 1 study filed under Hypoxia — fewer than ten, so there is no comparison to draw.
15 of the studies in Hypoxia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07748884Second Affiliated Hospital of Wenzhou Medical UniversityComparing Esketamine and Remazolam With Propofol for Breathing Safety in Pediatric Gastroscopy | 2026-12 |
| NCT07395596First Affiliated Hospital of Zhejiang UniversityRemimazolam for Bronchoscopy in High-Risk Patients | 2026-12 |
| NCT07307560Zhejiang UniversityHigh-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients | 2026-12-01 |
| NCT07051980Zhejiang UniversityFeasibility and Safety of Supraglottic Oxygen Delivery Via an Endotracheal Tube for Non-intubated ERCP Anesthesia: A Two-Stage Phase II Clinical Study | 2026-12-02 |
| NCT06966934Nanjing First Hospital, Nanjing Medical UniversityNasopharyngeal Airway Combined With Nasal High-flow Oxygen Therapy During Painless Gastroscopy in Obesity Patients | 2026-12-15 |
Add all 15 to your calendar (.ics) → With an account.
Among the 97 studies in Hypoxia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational study aims to develop and evaluate prediction models for low blood oxygen levels (hypoxemia) in adult patients undergoing gastroscopy, colonoscopy, or combined gastrointestinal endoscopy under anesthesia. The study will also assess patient flow and waiting times during different stages of endoscopy care.
Low blood oxygen levels may occur during anesthesia and recovery from endoscopy. Medical-grade wireless wearable monitoring devices can continuously record vital signs as patients move through preparation, examination, transfer, and recovery areas. The investigators will analyze monitoring data, routine clinical information, and the time spent at different stages of care to identify factors associated with hypoxemia and potentially avoidable nonmedical waiting time.
This study will be conducted at the First Affiliated Hospital of Chongqing Medical University. Approximately 772 adult participants are planned for enrollment in the current study phase. All participants will receive routine anesthesia, endoscopy, monitoring, and recovery care. The study will not change clinical treatment decisions, and prediction model results will not be used to guide patient care.
The findings may support future improvements in patient safety monitoring, hypoxemia risk assessment, and endoscopy workflow efficiency. Participants may not receive any direct medical benefit from taking part in this study.
Background and Rationale Hypoxemia is an important safety concern during gastrointestinal endoscopy under anesthesia. Changes in oxygen saturation may occur during both the procedure and the recovery period. Continuous monitoring using medical-grade wireless wearable devices may provide useful physiological data for predicting hypoxemia. In addition, the time required for different stages of endoscopy care may be influenced by patient characteristics, clinical needs, and operational factors. Distinguishing medically necessary care from avoidable nonmedical waiting may help improve workflow efficiency without compromising patient safety.
Study Design and Data Collection This investigator-initiated, prospective observational cohort study will be conducted at the First Affiliated Hospital of Chongqing Medical University. The current phase involves single-center model development and internal validation.
Adult patients scheduled for gastroscopy, colonoscopy, or combined gastrointestinal endoscopy under anesthesia will be assessed for eligibility and enrolled after written informed consent.
Medical-grade wireless wearable monitoring devices already used in routine clinical care will provide continuous physiological data, including peripheral oxygen saturation (SpO2), heart rate, and signal quality information. Additional study data will include routine pre-anesthesia assessments, patient characteristics, anesthesia and endoscopy records, airway management, recovery information, and workflow timestamps. Simple noninvasive measurements, including neck circumference and thyromental distance, will also be collected.
Hypoxemia Prediction Two prediction objectives will be evaluated. Model A will use information available before the first administration of anesthetic medication to predict hypoxemia occurring between the first anesthetic dose and endoscope removal.
Model B will evaluate the risk of hypoxemia during recovery, from completion of handover to the recovery area until the patient first meets discharge criteria. Development of Model B will depend on the availability of sufficient outcome events and data.
Hypoxemia will be defined as an SpO2 below 90%, after excluding measurement artifacts. Prediction models will be developed and internally validated using prespecified statistical and machine-learning methods. Additional temporal and external validation may be conducted in subsequent study phases after the required approvals.
Workflow Efficiency Assessment Standardized timestamps will be collected across patient check-in, preparation, monitoring, examination, transfer, recovery, discharge, and room turnover. Risk-adjusted analyses will assess variations in the duration of different workflow stages.
The main workflow efficiency outcome will be the cumulative duration of system-attributable nonmedical waiting time, confirmed by structured documentation of operational causes. Time required for necessary medical treatment, monitoring, and recovery will not be classified as avoidable waiting.
Patient Safety and Study Procedures This study is observational and will not alter routine anesthesia, endoscopy, monitoring, treatment, recovery, or discharge decisions. Prediction model results will not be disclosed to the clinical team for decision-making during the current study phase.
Research data will be de-identified and handled using appropriate data protection procedures. Available hospital records may be reviewed within 24 hours after discharge from the endoscopy center to identify relevant safety events. No additional invasive procedures or study-directed treatments will be performed.
The study population will consist of adult patients aged 18 years or older who are scheduled to undergo gastroscopy, colonoscopy, or combined gastrointestinal endoscopy under anesthesia at the First Affiliated Hospital of Chongqing Medical University, China. Potential participants will be identified through routine pre-anesthesia assessment and outpatient clinical services. Eligible patients with an ASA-PS classification of I-III who receive routine medical-grade wireless wearable monitoring will be invited to participate after screening. Written informed consent will be obtained before enrollment. Approximately 772 participants are planned for the current single-center observational study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort consists of adult patients aged 18 years or older who are scheduled to undergo gastroscopy, colonoscopy, or combined gastrointestinal endoscopy under anesthesia at the First Affiliated Hospital of Chongqing Medical University. Eligible patients have an American Society of Anesthesiologists Physical Status (ASA-PS) classification of I-III and provide written informed consent. All participants receive routine anesthesia, endoscopic examination, and medical-grade wireless wearable monitoring according to standard clinical practice. Physiological monitoring data, clinical information, and workflow timestamps will be collected prospectively for hypoxemia prediction model development and workflow efficiency assessment. No additional study-directed clinical intervention will be performed.
Incidence of Hypoxemia During Gastrointestinal Endoscopy
The proportion of participants experiencing at least one episode of hypoxemia between the first administration of anesthetic medication (T6) and endoscope removal (T8). Hypoxemia is defined as peripheral oxygen saturation (SpO2) below 90% at any time, after exclusion of measurement artifacts caused by movement, poor perfusion, or sensor displacement. Events will be adjudicated using monitoring data and clinical records.
Time frame: From the first administration of anesthetic medication until endoscope removal, during the endoscopy procedure.
Cumulative System-Attributable Nonmedical Waiting Time
The cumulative duration, in minutes, of system-attributable nonmedical waiting time per participant. Waiting episodes must have a documented operational cause, traceable start and end times, and no ongoing medical need for treatment, observation, or technical management. Operational causes include delays related to equipment, procedure rooms, staffing, recovery beds, transportation, handover, documentation, patient education, accompanying persons, cleaning, or supply preparation. Medically necessary care and recovery time will be excluded.
Time frame: From check-in at the endoscopy center until actual departure from the endoscopy center, on the day of the endoscopy procedure.
Incidence of Hypoxemia During Postanesthesia Recovery
The proportion of eligible participants experiencing hypoxemia (SpO2 below 90%, after artifact exclusion) after completion of handover to the recovery area (T10) and before first meeting discharge criteria (T12). The analysis will include participants without the recovery-period target event at T10 who have the required landmark variables. Formal model development is conditional on sufficient outcome events.
Time frame: From completion of handover to the postanesthesia recovery area until the participant first meets discharge criteria, on the day of the endoscopy procedure.
Incidence of Severe Hypoxemia
The proportion of participants experiencing severe hypoxemia, defined as SpO2 below 75%, or SpO2 between 75% and 90% lasting at least 60 seconds, according to the study protocol.
Time frame: From the first administration of anesthetic medication until the participant first meets discharge criteria, on the day of the endoscopy procedure.
Ratio of Hypoxemia Area Under the Curve to Duration
The area under the SpO2 curve for measurements below 90% divided by the cumulative duration of SpO2 below 90%, according to the prespecified analysis methodology.
Time frame: From the first administration of anesthetic medication until the participant first meets discharge criteria, on the day of the endoscopy procedure.
Incidence of Clinically Recognized Respiratory Events
The number and proportion of participants with clinically recognized apnea, airway obstruction, laryngospasm, bronchospasm, regurgitation, or aspiration. Event types will be reported separately.
Time frame: From the first administration of anesthetic medication until the participant first meets discharge criteria, on the day of the endoscopy procedure.
Incidence of Airway Interventions
The number and proportion of participants requiring positional adjustment, jaw thrust, increased oxygen flow, oropharyngeal or nasopharyngeal airway placement, positive-pressure mask ventilation, or unplanned tracheal intubation. Intervention types will be reported separately.
Time frame: From the first administration of anesthetic medication until the participant first meets discharge criteria, on the day of the endoscopy procedure.
Incidence of Hypotension
The proportion of participants with systolic blood pressure below 90 mmHg or a decrease greater than 30% from baseline. Treatment for hypotension will also be documented.
Time frame: From the first administration of anesthetic medication until the participant first meets discharge criteria, on the day of the endoscopy procedure.
Incidence of Bradycardia
The proportion of participants with heart rate below 50 beats per minute. Treatment for bradycardia will also be documented.
Time frame: From the first administration of anesthetic medication until the participant first meets discharge criteria, on the day of the endoscopy procedure.
Occurrence of Major Clinical Complications
The number and type of major clinical complications, including severe gastrointestinal bleeding, gastrointestinal perforation, unplanned emergency department transfer, intensive care unit admission or hospitalization, cardiac arrest, and death. Individual event categories will be reported separately.
Time frame: From check-in at the endoscopy center through 24 hours after actual departure from the endoscopy center.
Total Endoscopy Center Length of Stay
Total time in minutes from endoscopy center check-in (T1) to actual departure from the endoscopy center (T13).
Time frame: From check-in at the endoscopy center until actual departure from the endoscopy center, on the day of the endoscopy procedure.
Duration of Individual Endoscopy Workflow Stages
Duration in minutes of each adjacent workflow stage from T1 through T13, including preparation, examination, transfer, recovery, and discharge-related stages. Stage-specific values will be reported.
Time frame: From check-in at the endoscopy center until actual departure from the endoscopy center, on the day of the endoscopy procedure; each consecutive workflow stage will be assessed separately.
Procedure Room Turnover Time
Time in minutes from a participant leaving the procedure area (T9) until the next patient enters the same procedure room (T14). Prespecified exceptions will be excluded or reported separately.
Time frame: From departure of the participant from the procedure area until the next patient enters the same procedure room, on the day of the endoscopy procedure.
Risk-Adjusted Excess Workflow Duration
The difference between observed and expected workflow duration estimated using prespecified risk-adjusted stage-specific time models. Results will be evaluated by workflow stage.
Time frame: From check-in at the endoscopy center until actual departure from the endoscopy center, on the day of the endoscopy procedure; each workflow stage will be evaluated separately.
Plan to share: No — De-identified individual participant data (IPD) may be made available upon reasonable request to the corresponding author following publication of the primary study findings. Data sharing will be subject to approval by the relevant institutional ethics committee and execution of a data use agreement.
Start is estimated for Dec 2026; primary completion for Apr 2028, 16 months later.
Of 125 non-industry observational studies under Hypoxia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 74. This study's planned 16 months is below that.
Counting every sponsor, half of 155 studies reached it within 14 months; a quarter within 3 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Min Su